Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Current Leases (2023 - 2025)

Historic Current Leases for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $2.2 million.

  • Inhibrx Biosciences' Current Leases rose 2245.23% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 2245.23%. This contributed to the annual value of $1.6 million for FY2024, which is 2268.54% down from last year.
  • Inhibrx Biosciences' Current Leases amounted to $2.2 million in Q3 2025, which was up 2245.23% from $2.2 million recorded in Q2 2025.
  • Inhibrx Biosciences' Current Leases' 5-year high stood at $2.2 million during Q3 2025, with a 5-year trough of $1.6 million in Q4 2024.
  • Moreover, its 3-year median value for Current Leases was $2.1 million (2023), whereas its average is $2.0 million.
  • Per our database at Business Quant, Inhibrx Biosciences' Current Leases tumbled by 2268.54% in 2024 and then soared by 2245.23% in 2025.
  • Inhibrx Biosciences' Current Leases (Quarter) stood at $2.1 million in 2023, then fell by 22.69% to $1.6 million in 2024, then surged by 40.88% to $2.2 million in 2025.
  • Its Current Leases was $2.2 million in Q3 2025, compared to $2.2 million in Q2 2025 and $2.0 million in Q1 2025.